YU59400A - Azabiciklični ligandi 5ht1 receptora - Google Patents

Azabiciklični ligandi 5ht1 receptora

Info

Publication number
YU59400A
YU59400A YU59400A YU59400A YU59400A YU 59400 A YU59400 A YU 59400A YU 59400 A YU59400 A YU 59400A YU 59400 A YU59400 A YU 59400A YU 59400 A YU59400 A YU 59400A
Authority
YU
Yugoslavia
Prior art keywords
azabicyclic
receptor ligands
compound
formula
pharmaceutical compositions
Prior art date
Application number
YU59400A
Other languages
English (en)
Inventor
Gene Michael Bright
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU59400A publication Critical patent/YU59400A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Luminescent Compositions (AREA)

Abstract

Ovaj pronalazak se odnosi na jedinjenja formule (I). Ova jedinjenja su korisna psihoterapeutska sredstva.[A compound of formula (I), wherein Z and Q are as defined in the specification, to pharmaceutical compositions containing them and to their medicinal use.
YU59400A 1998-04-09 1999-03-18 Azabiciklični ligandi 5ht1 receptora YU59400A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8123798P 1998-04-09 1998-04-09

Publications (1)

Publication Number Publication Date
YU59400A true YU59400A (sh) 2003-10-31

Family

ID=22162936

Family Applications (1)

Application Number Title Priority Date Filing Date
YU59400A YU59400A (sh) 1998-04-09 1999-03-18 Azabiciklični ligandi 5ht1 receptora

Country Status (41)

Country Link
US (2) US6525048B1 (sh)
EP (1) EP1070065B1 (sh)
JP (1) JP3496759B2 (sh)
KR (1) KR100378931B1 (sh)
CN (1) CN1117092C (sh)
AP (1) AP1175A (sh)
AR (1) AR015751A1 (sh)
AT (1) ATE248838T1 (sh)
AU (1) AU749254B2 (sh)
BG (1) BG104915A (sh)
BR (1) BR9909522A (sh)
CA (1) CA2327782A1 (sh)
CO (1) CO5080727A1 (sh)
CZ (1) CZ20003684A3 (sh)
DE (1) DE69910997T2 (sh)
DK (1) DK1070065T3 (sh)
DZ (1) DZ2756A1 (sh)
EA (1) EA003400B1 (sh)
ES (1) ES2204154T3 (sh)
HK (1) HK1035719A1 (sh)
HR (1) HRP20000653A2 (sh)
HU (1) HUP0102400A3 (sh)
ID (1) ID26086A (sh)
IL (1) IL138629A0 (sh)
IS (1) IS5641A (sh)
MA (1) MA26619A1 (sh)
MY (1) MY133390A (sh)
NO (1) NO20005004L (sh)
NZ (1) NZ507010A (sh)
OA (1) OA11496A (sh)
PA (1) PA8469101A1 (sh)
PE (1) PE20000413A1 (sh)
PL (1) PL343408A1 (sh)
PT (1) PT1070065E (sh)
SK (1) SK14782000A3 (sh)
TN (1) TNSN99056A1 (sh)
TR (1) TR200002932T2 (sh)
TW (1) TW555758B (sh)
WO (1) WO1999052907A1 (sh)
YU (1) YU59400A (sh)
ZA (1) ZA992596B (sh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
AU762934B2 (en) * 1999-09-03 2003-07-10 Allergan Sales, Llc Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
GB2362826A (en) * 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
DE60229123D1 (de) * 2001-02-20 2008-11-13 Dinan Timothy Gerard Behandlung von fibromyalgie mit pindolol
MXPA05009660A (es) * 2003-03-12 2005-10-20 Pfizer Prod Inc Derivados azabiciclicos de piridiloximetilo y bencisoxazol.
WO2005082370A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
AR048112A1 (es) 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
JP2008503560A (ja) * 2004-06-22 2008-02-07 ファイザー・プロダクツ・インク ジアザビシクロ系のヒスタミン−３受容体アンタゴニスト
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
BRPI0514793A (pt) * 2004-09-10 2008-06-24 Pfizer Prod Inc uso de derivados azabicìclicos de benzisoxazol e piridiloximetila na preparação de um medicamento para o tratamento de distúrbios cognitivos
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
CA2118936A1 (en) * 1991-09-25 1993-04-01 Gene M. Bright Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines
US5262428A (en) * 1992-03-13 1993-11-16 Wake Forest University Biologically active tropane derivatives
JP2753146B2 (ja) * 1992-06-16 1998-05-18 ファイザー・インコーポレーテッド ビス−アザー二環式抗不安薬の製法および中間体
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
WO1996010570A1 (en) * 1994-09-30 1996-04-11 Pfizer Inc. NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
EA200000910A1 (ru) 2001-04-23
HRP20000653A2 (en) 2001-04-30
KR20010042527A (ko) 2001-05-25
DE69910997D1 (de) 2003-10-09
DK1070065T3 (da) 2003-11-24
TW555758B (en) 2003-10-01
AP9901502A0 (en) 1999-06-30
ID26086A (id) 2000-11-23
JP2002511469A (ja) 2002-04-16
NO20005004L (no) 2000-11-27
AU3268799A (en) 1999-11-01
US20030181458A1 (en) 2003-09-25
CO5080727A1 (es) 2001-09-25
HUP0102400A3 (en) 2002-10-28
ES2204154T3 (es) 2004-04-16
OA11496A (en) 2004-05-14
CA2327782A1 (en) 1999-10-21
US6887905B2 (en) 2005-05-03
PT1070065E (pt) 2003-12-31
NO20005004D0 (no) 2000-10-04
AR015751A1 (es) 2001-05-16
DZ2756A1 (fr) 2003-09-15
US6525048B1 (en) 2003-02-25
HUP0102400A2 (hu) 2001-11-28
PA8469101A1 (es) 2000-09-29
IL138629A0 (en) 2001-10-31
TR200002932T2 (tr) 2001-01-22
CN1305477A (zh) 2001-07-25
AU749254B2 (en) 2002-06-20
PE20000413A1 (es) 2000-05-25
HK1035719A1 (en) 2001-12-07
EP1070065B1 (en) 2003-09-03
ATE248838T1 (de) 2003-09-15
TNSN99056A1 (fr) 2005-11-10
BG104915A (en) 2001-07-31
NZ507010A (en) 2003-05-30
WO1999052907A1 (en) 1999-10-21
BR9909522A (pt) 2000-12-19
DE69910997T2 (de) 2004-05-19
SK14782000A3 (sk) 2002-06-04
PL343408A1 (en) 2001-08-13
JP3496759B2 (ja) 2004-02-16
EA003400B1 (ru) 2003-04-24
MA26619A1 (fr) 2004-12-20
ZA992596B (en) 2000-10-08
CN1117092C (zh) 2003-08-06
CZ20003684A3 (cs) 2002-03-13
AP1175A (en) 2003-06-04
MY133390A (en) 2007-11-30
KR100378931B1 (ko) 2003-04-07
EP1070065A1 (en) 2001-01-24
IS5641A (is) 2000-09-26

Similar Documents

Publication Publication Date Title
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
YU57600A (sh) Derivarti biciklične hidroksaminske kiseline
MY137535A (en) New pyrrolidinium derivatives
SE9904505D0 (sv) Novel compounds
SE9504661D0 (sv) New compounds
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
MY134568A (en) Cb2 receptor agonists
MX9700885A (es) Nuevas heteroariloxazolidinonas.
DK1157037T3 (da) GCSF-konjugater
IL154988A0 (en) Pharmaceutical compositions containing a 5-ht3 receptor antagonist
WO2004060882A8 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
SE9704545D0 (sv) Novel compounds
SE9704544D0 (sv) Novel compounds
CA2414095A1 (en) Novel compounds
TR200102800T2 (tr) Yeni bileşikler.
MY127144A (en) New anticholinergics which may be used as medicaments as well as processes for preparing them
YU59400A (sh) Azabiciklični ligandi 5ht1 receptora
GB9914486D0 (en) Medicaments
SE9901875D0 (sv) Novel compounds
SE9704546D0 (sv) Novel compounds
AU2003269327A1 (en) Tetrahydroquinoline derivatives as crth2 antagonists
IL94433A0 (en) Aminophenol derivatives,their preparation and pharmaceutical compositions containing them
AU3850600A (en) Dalda analogs and their use
BG100069A (en) Amidine derivatives containing heterocylic groups, their preparation and application
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use